BioCentury
ARTICLE | Clinical News

Adipothermics, Inc. preclinical data

September 12, 2011 7:00 AM UTC

Researchers at Scripps Florida and the Dana-Farber Cancer Institute reported that a non-agonist PPAR gamma targeted compound significantly improve insulin sensitivity vs. vehicle-treated controls in mouse models of Type II diabetes. Additionally, the compound reduced insulin levels and improved glucose tolerance with potency comparable to that of Avandia rosiglitazone, but without significant weight gain or fluid retention. The researchers said the PPAR compound acts by reducing the receptor's phosphorylation by cyclin dependent kinase 5 (CDK5). Data were published in Nature. ...